Tables Guide:
Table 1. Characteristics of patients with relapsed or refractory Ewing sarcoma and osteosarcoma (n=12)
Table 2. Adverse events that either occurred in >10% of patients at any grade, or occurred at grade ≥3 in patients with relapsed or refractory Ewing sarcoma and osteosarcoma treated with the combination of cabozantinib, topotecan and cyclophosphamide (n=12). Adverse events considered unrelated or unlikely related to protocol therapy are excluded.
Table 3. Summary of objective best response in patients with relapsed or refractory Ewing sarcoma and osteosarcoma treated with a combination of cabozantinib, topotecan and cyclophosphamide (n=12).